Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Accepts Ascendis Pharma’s sBLA for TransCon™ hGH in Adults with Deficiency
Details : TransCon hGH (lonapegsomatropin) is a once-weekly growth hormone, is designed to deliver unmodified somatropin. which is being evaluated for the treatment of growth hormone deficiency.
Product Name : TransCon hGH
Product Type : Hormone
Upfront Cash : Inapplicable
December 12, 2024
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA declines to approve Novo Nordisk's weekly insulin
Details : Awiqli (insulin icodec) is a once-weekly basal insulin analogue, which is being evaluated for the treatment of patients with Diabetes Mellitus, Type 2 & Type 1.
Product Name : Awiqli
Product Type : Peptide
Upfront Cash : Inapplicable
October 07, 2024
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascendis Submits BLA To FDA For TransCon™ hGH For Growth Hormone Deficiency
Details : Skytrofa (lonapegsomatropin) is a once-weekly growth hormone, is designed to deliver unmodified somatropin. Being evaluated for growth hormone deficiency in adults.
Product Name : Skytrofa
Product Type : Hormone
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dasiglucagon
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zealand Updates on Dasiglucagon For Congenital Hyperinsulinism in U.S.
Details : Zegalogue (dasiglucagon) is a glucagon receptor agonist, peptide drug candidate, which is currently being evaluated for the treatment of hypoglycemia in pediatric patients.
Product Name : Zegalogue
Product Type : Hormone
Upfront Cash : Inapplicable
September 10, 2024
Lead Product(s) : Dasiglucagon
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Icodec,Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3a Shows IcoSema's Non-Inferior HbA1c Reduction Compared To Daily Insulin Treatment
Details : IcoSema (Insulin Icodec) is fixed-ratio combination of a once-weekly basal insulin icodec and once-weekly semaglutide. It is under phase 3 clinical development for the treatment of type 2 diabetes.
Product Name : IcoSema
Product Type : Peptide
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : Insulin Icodec,Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA panel votes against Novo Nordisk's weekly insulin in type 1 diabetes patients
Details : Awiqli (insulin icodec) is a once-weekly basal insulin analogue , which is being evaluated for the treatment of patients with Diabetes Mellitus, Type 2 & Type 1.
Product Name : Awiqli
Product Type : Peptide
Upfront Cash : Inapplicable
May 24, 2024
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ascendis must wait 3 more months for FDA verdict on TransCon PTH
Details : TransCon PTH (palopegteriparatide) approved in EU & UK is a PTH-R agonist, SC injection for the treatment of Hypoparathyroidism. FDA has extended the PDUFA date to 14 August 2024.
Product Name : TransCon PTH
Product Type : Hormone
Upfront Cash : Inapplicable
May 14, 2024
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Semaglutide Shows 24% Reduction in Kidney Disease-Related Events Risk in Type 2 Diabetes
Details : Ozempic (semaglutide) belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It is being evaluated for type 2 diabetes and chronic kidney disease.
Product Name : Ozempic
Product Type : Peptide
Upfront Cash : Inapplicable
May 03, 2024
Lead Product(s) : Semaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Awiqli (once-weekly insulin icodec) Recommended for Approval for Diabetes in Europe
Details : Awiqli (insulin icodec) is a once-weekly basal insulin analogue , which is being evaluated for the treatment of patients with Diabetes Mellitus, Type 2 & Type 1.
Product Name : Awiqli
Product Type : Peptide
Upfront Cash : Inapplicable
March 21, 2024
Lead Product(s) : Insulin Icodec
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TransCon hGH (lonapegsomatropin) is a once-weekly growth hormone, is designed to deliver unmodified somatropin. which is being evaluated in phase 3 clinical trials for the treatment of growth hormone deficiency.
Product Name : Skytrofa
Product Type : Hormone
Upfront Cash : Inapplicable
December 19, 2023
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable